A

· Abbott Laboratories. Divalproex sodium : M87-016 study - M88-267 study. Data on file. 1996.

· Alexanderson, B., Evans, D.A.P. & Sjöqvist, F. Steady-state plasma levels of nortriptyline in twins : influence of genetic factors and drug therapy. Br. Med. J. 1969 ; 2 : 764-768.

· Alfredsson, G., Lindberg, M. & Sedvall, G. The presence of 7-hydroxychlorpromazine in CSF of chlorpromazine-treated patients. Psychopharmacology. 1982; 77: 376-378.

· Alfredsson, G., Bjerkenstedt, L., Edman, G. et al. Relationship between drug concentrations in serum and CSF, clinical effects and monoaminergic variables in schizophrenic patients treated with sulpiride or chlorpromazine. Acta Psychiatr. Scand. 1984; 69: 49-74.

· Altamura, A.C., Montgomery, S.A. & Wernicke, J.F. The evidence for 20 mg a day of fluoxetine as the optimal in the treatment of depression. Br. J. Psychiatry. 1988 ; 153 (suppl. 3) : 109-112.

· Altamura, A.C., Tacchini, G.L. & Maes, M. Haloperidol plasma 'threshold' levels for relapse prevention in schizophrenia: a study with haloperidol decanoate. Eur. Neuropsychopharmacol. 1995; 5 (suppl): 55-58.

· Alvarez, M.E. Plasma and red cell lithium in affective disorders. Br. J. Psychiatry. 1983 ; 143 : 311-312.

· Alvir, J.M.J., Jeffrey, P.H., Lieberman, J.A. et al. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N. Engl. J. Med. 1993; 329: 162-167.

· Ambrosini, P.J., Bianch, M.D., Metz, C. et al. Evaluating clinical response of open nortriptyline pharmacotherapy in adolescent major depression. J. Child. Adolesc. Psychopharmacol. 1994; 4: 233-244.

· Amin, M.M., Cooper, R. & Khalid, R. A comparison of desipramine and amitriptyline plasma levels and therapeutic response. Psychopharmacol. Bull. 1978 ; 14 : 45.

· Amin, M.M., Lehmann, H. & Mirmiran, J. A double-blind, placebo controlled dosefinding study with sertraline. Psychopharmacol. Bull. 1989 ; 25 : 164-167.

· Amitai, Y., Kennedy, E.J., DeSandre, P. et al. Distribution of amitriptyline and nortriptyline in blood: role of alpha-1-glycoprotein. Ther. Drug Monit. 1993; 15: 267-273.

· Amsterdam, J., Brunswick, D. & Mendels, J. The clinical application of tricyclic antidepressant pharmacokinetics and plasma levels. Am. J. Psychiatry. 1980 ; 137 : 653-662.

· Amsterdam, J.D., Brunswick, D.J., Potter, L. et al. Desipramine and 2-hydroxydesipramine plasma levels in endogenous depressed patients. Lack of correlation with therapeutic response. Arch. Gen. Psychiatry. 1985; 42: 361-364.

· Amsterdam, J.D., Rybakowski, J., Gottlieb, J. et al. Kinetics of erythrocyte lithium-sodium countertransport in patients with affective illness before and during lithium therapy. J. Affect. Dis. 1988 ; 14 : 75-81.

· Amsterdam, J.D., Fawcett, J., Quitkin, F.M. et al. Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. Am. J. Psychiatry. 1997; 154: 963-969.

· APA Task Force on the use of laboratory test in psychiatry. Tricyclic antidepressants-blood level measurements and clinical outcome : an APA Task Force report. Am. J. Psychiatry. 1985; 142: 155-162.

· Aronson, T.A. A naturalistic study of imipramine in panic disorder and agoraphobia. Am. J. Psychiatry. 1987; 144: 1014-1019.

· Asberg, M., Cronholm, B., Sjoqvist, F. et al. Correlation of subjetive side effects with plasma concentrations of nortriptyline. Br. Med. J. 1970 ; 4 : 18-21.

· Asberg, M., Cronholm, B., Sjoqvist, F. & Tuck, D. Relationship between plasma levels and therapeutic effect of nortriptyline. Br. Med. J. 1971 ; 3 : 331-334.

· Asberg, M. Plasma nortriptyline levels - relationship to clinical effects. Clin. Pharmacol. Ther. 1974 ; 16 : 215-229.

· Axelsson, R. & Martensson, E. Side effects of thioridazine and their relationship with the serum concnetrations of the drug and its main metabolites. Curr. Ther. Res. 1980; 28: 463-489.

· Aymard, N., Viala, A., Stein, I. et al. Pharmacoclinical correlations in schizophrenic patients treated with haloperidol decanoate: clinical evaluations, concentrations of plasma and red blood cell haloperidosl and its reduced metabolite, and plasma homovanillic acid. Prog. Neuro-Psychopharmacol. & Biol. Psychiat. 1995; 19: 1119-1135.

· Azarnoff, D.L. Application of blood level data to clinical trials. Clin. Pharmacol. Ther. 1974 ; 16 (part 2) : 183-188.

Principio de página

B

· Bacopoulos, W.G., Hattox, S.E. & Roth, R.H. 3-4-dihydroxiphenylacetic acid and homovanillic acid in rat plasma: possible indicators of central dopaminergic activity. Eur. J. Pharmacol. 1979; 58: 225-236.

· Bailey, D.N., Van Dyke, C., Langou, R.A. et al. Tricyclic antidepressants: plasma levels and clinical findings in overdose. Am. J. Psychiatry. 1978; 135: 1325-1328.

· Baldessarini, R.J., Cohen, B.M. & Teicher, M.H. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch. Gen. Psychiatry. 1988 ; 45 : 79-91.

· Baldessarini, R.J. & Frankenburg, F.R. Clozapine: a novel antipsychotic agent. N. Engl. J. Med. 1991; 324: 746-754.

· Baumann, P., Jonzier-Perey, M., Koeb, L. et al. Amitriptyline pharmacokinetics and clinical response: I. Free and total plasma amitriptyline and nortriptyline. Int. Clin. Psychopharmacol. 1986; 1: 89-101.

· Beasley, C.M., Bosomworth, J.C. & Wernicke, J.F. Fluoxetine : Realtionships among dose, response, adverse events, and plasma concentrations in the treatment of depression. Psychopharmacol. Bull. 1990 ; 26 : 18-24.

· Biederman, J., Baldessarini, R.J., Wright, V. et al. A double-blind placebo controlled study of desipramine in the treatment of ADD. II : serum drug levels and cardiovascular findings. J. Am. Acad. Child Adolesc. Psychiatry. 1989 ; 28 : 903-911.

· Biederman, J. Sudden death in children treated with a tricyclic antidepressant. J. Am. Acad. Child Adolesc. Psychiatry. 1991; 30: 495-498.

· Bigelow, L.B., Kirch, D.G., Brown, T. et al. Absence of relationship of serum haloperidol concentration and clinical response in chronic schizophrenia: a fixed-dose study. Psychopharmacol. Bull. 1985; 21: 66-68.

· Biggs, J.T., Spiker, D.G., Petit, J.M. et al. Tricyclic antidepressant overdose. Incidence of symptoms. JAMA. 1977a ; 238 : 135-138.

· Biggs, J.T., Giordina, E.G.V., Perel, J.M. et al. Cardiac antiarrhythmic effect of imipramine hydrochloride. N. Engl. J. Med. 1977 ; 296 : 206-208.

· Birmaher, B., Ryan, N.D., Williamson, D.E. et al. Childhood and adolescent depression: a review of the past 10 years . Part I. J. Am. Acad. Child Adolesc. Psychiatry. 1996; 35: 1427-1439.

· Bjerkenstedt, L., Flyckt, L., Fredricson-Overo, K. & Lingjaerde, O. Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram. A double-blind comparison of three dose concnentrations. Eur. J. Clin. Pharmacol. 1985 ; 28 : 553-557.

· Bjorndal, N., Bjerre, M, Gerlach, J et al. High dosage haloperidol therapy in chronic schizophrenic patients: a double-blind study of clinical response, side effects, serum haloperidol, and serum prolactin. Psychopharmacology. 1980; 67: 17-23.

· Bleeker, J.A.C., Dingemans, P.M. & Frohn-De Winder, M.L. Plasma level and effect of low-dose haloperidol in acute psychosis. Psychopharmacol. Bull. 1984; 20: 317-319.

· Bolvig-Hansen, L. & Larsen, N-E. Therapeutic advantages of monitoring plasma concentrations of perphenazine in clinical practice. Psychopharmacology. 1985; 87: 16-19.

· Bond, A.J., Hally, D.M. & Lader, M.H. Plasma concentrations of benzodiazepines. Br. J. Clin. Psychopharmacol. 1977; 4: 51-56.

· Boulos, C., Kutcher, S., Gardner, D. et al. An open naturalistic trial of fluoxetine in adolescents and young adults with treatment-resistant major depression. J. Child Adolesc. Psychopharmacol. 1992; 2: 103-111.

· Bowden, C.L. & Fisher, J.G. Relationship of diazepam serum level to antianxiety effects. J. Clin. Psychopharmacol. 1982; 2: 110.

· Bowden, C.L., Brugger, A.M., Swann, A.C. et al. Efficacy of divalproex vs. lithium and placebo in the treatment of mania. JAMA. 1994; 271: 918-924.

· Bowden, C.L., Janicak, P.G., Orsulak, P. et al. Relation of serum valproate concentration to response in mania. Am. J. Psychiatry. 1996 ; 153 : 765-770.

· Boyer, W.F. & Lake, C.R. Initial severity and diagnosis influence the relationship of tricyclic plasma levels to response : a statistical review. J. Clin. Psychopharmacol. 1987 ; 7 : 67-71.

· Braithwaite, R.A., Goulding, R., Theano, G. et al. Plasma concentration of amitryptiline and clinical response in depressive illness. Lancet. 1972 ; 1 : 1297-1300.

· Braithwaite, R., Montgomery, S. & Dawling, S. Nortriptyline in depressed patients with high plasma levels, II. Clin. Pharmacol. Ther. 1978 ; 23 : 303-314.

· Breyer-Pfaff, U., Giedke, H., Gaertner, H.J. et al. Validation of a therapeutic plasma level range in amitriptyline treatment of depression. J. Clin. Psychopharmacol. 1989; 9: 116-121.

· Broadhurst, A.D., James, H.D., Corte, L.D. et al. Clomipramine plasma level and clinical response. Postgrad. Med. J. 1977 ; (suppl. 4) : 139-145.

· Browne, J.L., Perry, P.J., Alexander, B.E. et al. Pharmacokinetic protocol for predicting plasma nortriptyline levels. J. Clin. Psychopharmacol. 1983 ; 3 : 351-356.

· Brunswick, D.J., Amsterdam, J.D., Mendels, J. & Stern, S.L. Prediction of steady-state imipramine and desmethylimipramine plasma concentrations from single dose data. Clin. Pharmacol. Ther. 1979 ; 25 : 605-610.

· Burke, W.J., Hendricks, S.E., McArthur-Campbell, D. et al. Fluoxetine and norfluoxetine serum concentrations and clinical response in weekly versus daily dosing. Psychopharmacol. Bull. 1996; 32: 27-32.

· Burrows, G.D., Davies, B. & Scoggins, B.A. Plasma concentrations of nortriptyline and clinical response in depressive illness. Lancet. 1972 ; 2 : 619-623.

· Burrows, G.D., Scoggins, B.A., Turecek, L.R. et al. Plasma nortriptyline and clinical response. Clin. Pharmacol. Ther. 1974 ; 16 : 639-644.

· Burrows, G.D., Vohra, J., Hunt, D. et al. Cardiac effects of different tricyclic antidepressant drugs. Br. J. Psychiatry. 1976 ; 129 : 335-341.

Principio de página

C

· Cain, J.W. Poor response to fluoxetine: underlying depression, serotoninergic overstimulation or a "therapeutic window"? J. Clin. Psychiatry. 1992; 53: 272-277.

· Casper, R., Garver, D.L., Dekirmenjian, H. et al. Phenotiazinew levels in plasma and red blood cells. The relationship to clinical improvement in schizophrenia. Arch. Gen. Psychiatry. 1980; 37: 301-305.

· Centorrino, F., Baldessarini, R.J., Flood, J.G. et al. Relation of leukocyte counts during clozapine treatment to serum concentrations of clozapine and metabolites. Am. J. Psychiatry. 1995; 152: 610-612.

· Chamberlain, S., Hahn, P.M., Cassan, P. & Reid, R.L. Effect of menstrual cycle phase and oral contraceptive use on serum lithium levels after a loading dose of lithium in normal women. Am. J. Psychiatry. 1990 ; 147 : 907-909.

· Chang, W.H., Chen, T.Y., Lee, C.F. et al. Low plasma reduced haloperidol/ haloperdiol ratios in chinese patients. Biol. Psychiatry. 1987; 22: 1406-1408.

· Chang, W.H., Chen, T.Y., Lin, S.K. et al. Plasma catecholamine mewtabolites in schizophrenics: evidence for the two subtype concept. Biol. Psychiatry. 1990; 27: 510-518.

· Chang, W.H., Hwu, H.G., Lane, H.Y. et al. Dose-dependent reduced haloperidol/haloperidol ratios in schizophrenic patients. Psychiatry Res. 1991; 38: 215-225.

· Chitasombat, P., Willenbring, M.L., Maddux, T. et al. Reliability of methadone plasma levels in methadone maintenance. Am. J. Addictions. 1995; 4: 351-355.

· Chouinard, G., Jones, B.D., Annable, L. & Ross-Chouinard, A. Sex differences and tardive dyskinesia (letter). Am. J. Psychiatry. 1980 ; 137 : 507.

· Ciraulo, D.A., Antal, E.J. & Smith, R.B. The relationship of alprazolam dose steady-state plasma concentrations. J. Clin. Psychophramacol. 1990; 10: 27-32.

· Clein, P.D. & Riddle, M.A. Pharmacokinetics in children and adolescents. Child Adolesc. Psychiatr. Clin. North. Am. 1995; 4: 59-75.

· Clothier, J & Reed, K. Targeting therapeutic plasma levels of nortriptyline from test dose plasma concentrations. J. Clin. Psychopharmacol. 1984 ; 4 : 216-217.

· Coccaro, E.F., Adan, F., Allen, D. et al. Plasma-serum differences in the assessment of tricyclic antidepresssant blood levels. Int. Clin. Psyhcopharmacol. 1987; 2: 217-224.

· Cohen, I., Bunney, W.E., Cole, J.O. et al. The current status of lithium therapy: report of the APA task force. Am. J. Psychiatry. 1975; 133: 997-1001.

· Cohen, B.M., Lipinski, J.F. & Waternaux, C. A fixed dose study of the plasma concentration and clinical effects of thioridazine and its major metabolites. Psychopharmacology (Berl). 1989; 97: 481-488.

· Colle, L.M., Belair, J.F., Di Feo, M. et al. Extended open-label fluoxetine treatment of adolescents with major depression. J. Child Adolesc. Psychopharmacol. 1994; 4: 225-232.

· Consensus Development Panel. NIMH/NIH Consensus Development Conference statement: mood disorders: pharmacologic prevention of recurrences. Am. J. Psychiatry. 1985; 142: 469-476.

· Cooper, T.B. & Simpson, G.M. Prediction of individual dosage of nortriptyline. Am. J. Psychiatry. 1978 ; 135 : 333-335.

· Coppen, A., Ghose, K., Montgomery, S., et al. Amitriptyline plasma-concentration and clinical effect : a World Health Organization collaborative study. Lancet. 1978 ; 1 : 63-66.

· Corona, G.L., Cucchi, M.L., Frattini, P. et al. Aspects of amitriptyline and nortriptyline plasma levels monitoring in depression. Psychopharmacology (Berl). 1990; 100: 334-338.

· Coryell, W., Miller, D. & Perry, P.J. Haloperidol plasma levels and dose optimization. Am. J. Psychiatry. 1998; 155: 48-53.

· Csernansky, J.G., Kaplan, J., Holman, C.A. et al. Serum neuroleptic activity, prolactin and tardive dyskinesia in schizophrenic outpatients. Psycxhopharmacology. 1983; 81: 115-118.

· Curry, S.H., Marshall, J.H.L., Davis, J.M. et al. Chlorpromazine plasma levels and effects. Arch. Gen. Psychiatry. 1970a; 22: 289-296.

· Curry, S.H., Davis, J.M., Janowsky, D.S. et al. Factors affecting chlorpromazine plasma levels in psychiatric patients. Arch. Gen. Psychiatry. 1970b; 22: 207-215.

· Curry, S.H. Concentration-effect relationship with major and minor tranquilizers. Clin. Pharmacol. Ther. 1974; 16: 192-197.

· Curry, S.H., Stewart, R.B., Springer, P.K. et al. Plasma trifluoperazine concentrations during high dose therapy. Lancet. 1981; 1: 395-396.

· Cutler, N.R., Zavadil, A.P., Eisdorfer, C. et al. Concentrations of desipramine in elderly women. Am. J. Psychiatry. 1981 ; 138 : 1235-1237.

Principio de página

D

· Dahl, S.G. Plasma level monitoring of antipsychotic drugs. Clinical utility. Clin. Pharmacokinet. 1986; 11: 36-61.

· Darby, J.K., Pasta, D.J., Elfand, L. et al. Risperidone dose and blood level varaiability: accumulation effects and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting. J. Clin. Psychopharmacol. 1997; 17: 478-484.

· Dasberg, H.H., van der Klijn, E., Guelen, P.J.R. et al. Plasma concentrations of diazepam and its metabolite N-desmethyldiazepam in relation to anxiolytic effect. Clin. Pharmacol. Ther. 1974; 15: 473-483.

· Davidson, J. Seizures and bupropion: a review. J. Clin. Psychiatry. 1989; 50: 256-261.

· Dávila, R., Manero, E., Zumarraga, M. et al. Plasma homovanillic acid as a predictor of response to neuroleptics. Arch. Gen. Psychiatry. 1988; 45: 564-567.

· Davis, J.M., Ericksen, S.E., Hurt, S. et al. Haloperidol plasma levels and clinical response: basic concepts and clinical data. Psychopharmacol. Bull. 1985; 21: 48-51.

· Dawling, S., Crome, P., Heyer, E.J. et al. Nortriptyline therapy in elderly patients : dosage prediction from plasma concentration at 24 hours after single 50 mg dose. Br. J. Psychiatry. 1981 ; 139 : 413-416.

· DeVane, C.L. Pharmacogenetics and drug metabolism of newer antidepressant drugs. J. Clin. Psychiatry. 1994 ; 55 (suppl.) : 38-47.

· Doddi, S., Rifkin, A., Karajgi, B. et al. Blood levels of haloperidol and clinical outcome in schizophrenia. J. Clin. Psychopharmacol. 1994; 14: 187-195.

· Dornseif, B.E., Dunlop, S.R., Potvin, J.H. & Wernicke, J.F. Effect of dose escalation after low-dose fluoxetine therapy. Psychopharmacol. Bull. 1989 ; 25 : 71-79.

· Dose, M. & Emrich, H.M. Acute mania. Practical therapeutic guidelines. CNS Drugs. 1995 ; 3 : 427-435.

· Dysken, M.W., Javaid, J.I., Chang, S.S. et al. Fluphenazine pharmacokinetics and therapeutic response. Psychopharmacology. 1981; 73: 205-210.

· Dysken, M.W., Kim, S.W., Vatassery, G. et al. Haloperidol decanoate pharmacokinetics in red blood cells and plasma. J. Clin. Psychopharmacol. 1992; 12: 128-132.

· Dysken, M.W., Johnson, S.B., Holden, L. et al. Haloperidol concentrations in patients with Alzheimer's dementia. Am. J. Geriatric Psychiatry. 1994; 2: 124-133.

Principio de página

E

· Edelbroek, P.M., Zitman, F.G., Schreuder, J.N. et al. Amitriptyline metabolism in relation to antidepressive effect. Clin. Pharmacol. Ther. 1984; 35: 467-473.

· Elizur, A., Shopsin, B., Gershon, S. et al. Intra : extracellular lithium ratios and clinical course in affective states. Clin. Pharmacol. Ther. 1972 ; 13 : 947-952.

· Emslie, G.J., Rush, A.J., Weinberg, W.A. et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch. Gen. Psychiatry. 1997; 54: 1031-1037.

· Ereshefsky, L., Sakalad, S.R., Jann, M.W. et al. Future of depot neuroleptic therapy: pharmacokinetic and pharmacodinamic approaches. J. Clin. Psychiatry. 1984a; 45 (suppl.): 50-59.

· Ereshefsky, L., Davis, C.M., Harrington, C.A. et al. Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients. J. Clin. Psychopharmacol. 1984b; 4: 138-142.

· Ereshefsky, L., Jann, M.W., Sakalad, S.R. et al. Bioavailability of psychotropic drugs : historical perspective and pharmacokinetic overview. J. Clin. Psychiatry. 1986 ; 47 : 6-15.

· Extein, I., Augusthy, K.A., Gold, M.S. et al. Plasma haloperidol levels and clinical response in acute schizophrenia. Psychopharmacol. Bull. 1982; 18: 156-158.   

Principio de página

F

· Fairbairn, A.F., Rowell, F.J., Hui, S.M. et al. Serum concentration of depot neuroleptics in tardive dyskinesia. Br. J. Psychiatry. 1983; 142: 579-583.

· Fara, M., Cohen, L., Reiter, S. et al. High dose fluoxetine in the treatment of depressed patients non-responding to a standard dose of fluoxetine. Biol. Psychiatry. 1991 ; 29 : 638s.

· Farde, L., Wiesel, F-A., Halldin, C. et al. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch. Gen. Psychiatry. 1988; 45: 71-76.

· Farde, L., Nordström, A-L., Wiesel, F-A. et al. Positron emission tomographicx analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch. Gen. Psychiatry. 1992; 49: 538-544.

· Fernandez de Gatta, M.M., Galindo, P., Rey, F. et al. The influence of clinical and pharmacological factors on enuresis treatment with imipramine. Br. J. Pharmacol. 1990; 30: 693-698.

· Fitchner, C.G., Jobe, T.H. & Brown, B.G. Possible therapeutic window for serotonin reuptake inhibitors. J. Clin. Psychiatry. 1992; 55: 36-38.

· Frances, A., Docherty, J.P. & Kahn, D.A. (eds.). The expert consensus guideline series : treatment of bipolar disorder. J. Clin. Psychiatry. 1996 ; 57 (suppl. 12A) : 5-42.

· Fredricson Overo, K. Fluorescence assay of citalopram and its metabolites in plasma by canning densitometry of thin-layer chromatograms. J. Chromatogr. 1991 ; 224 : 526-531.

· Freeman, T.W., Clothier, J.L., Pazzaglia, P. et al. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am. J. Psychiatry. 1992; 149: 108-111.

· Friedel, R.O. Relationship of desipramine plasma levels to therapeutic response: a critical reappraisal of the data. J. Clin. Psychiatry. 1984; 45: 46-49.

· Fritz, G.K., Rockney, R.M. & Yeung, A.S. Plasma levels and efficacy of imipramine treatment for enuresis. J. Am. Acad. Child Adolesc. Psychiatry. 1994; 33: 60-64.

Principio de página

G

· Gaertner, H.J., Golfinopoulos, G. & Breyer-Pfaff, U. Response to maprotiline treatment in depressive patients relationship to urinary MHPG excretion and plasma drug level. Pharmacopsychiatria. 1982; 15: 170-174.

· Garver, D.L., Dekirmenjian, H., Davis, J.M. et al. Neuroleptic drug levels and therapeutic response: preliminary observations with red blood cell bound butaperazine. Am. J. Psychiatry. 1977; 134: 304-307.

· Garver, D.L., Hirschowitz, J., Glicksteen, G.A. et al. Haloperidol plasma and red blood cells levels and clinical antipsychotic response. J. Clin. Psychopharmacol. 1984; 4: 133-137.

· Gelenberg, A.J., Wojcik, J.D., Falk, W.E. et al. Effects of lithium on the kidney. Acta Psychiatr. Scand. 1987; 75: 29-34.

· Gelenberg, A.J., Kane, J.M., Keller, M.B. et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N. Engl. J. Med. 1989 ; 321 : 1489-1493.

· Geller, B., Cooper, T.B., Chesnut, E.C. et al. Nortriptyline pharmacokinetic parameters in depressed children and adolescents : preliminary data. J. Clin. Psychopharmacol. 1984 ; 4 : 265-269.

· Geller, B., Cooper, T.B. & Chesnut, E.C. Serial monitoring and achievement of steady state nortriptyline plasma levels in depressed children and adolescents : preliminary data. J. Clin. Psychopharmacol. 1985 ; 5 : 213-216.

· Geller, B., Cooper, T.B., Chesnut, E.C. et al. Preliminary data on the relationship between nortriptyline plasma level and response in depressed children. Am. J. Psychiatry. 1986 ; 143 : 1283-1286.

· Geller, B., Cooper, T.B., Schluchter, M.D. et al. Child and adolescent nortriptyline single dose pharmacokinetic parameters: Final report. J. Clin. Psychopharmacol. 1987; 7: 321-323.

· Geller, B., Cooper, T.B., McCombs, H.G. et al. Double-blind placebo-controlled study of nortriptyline in depressed children using a "fixed plasma level" design. Psychopharmacol. Bul. 1989 ; 25 : 101-108.

· Geller, B., Cooper, T.B., Graham, D.L. et al. Double-blind placebo-controlled study of nortriptyline in depressed adolescents using a ``fixed plasma level'' design. Psychopharmacol. Bull. 1990; 26: 85-90.

· Geller, B., Cooper, T.B., Graham, D.L. et al. Pharmacokinetically designed double-blind placebo-controlled study of nortriptyline in 6- to 12-year-olds with major depressive disorder. J. Am. Acad. Child Adolesc. Psychiatry. 1992; 31: 34-44.

· Gerlach, J., Behnke, K., Heltberg, J. et al. Sulpiride and haloperidol in schizophrenia: a double-blind cross-over study of therapeutic effect, side effects and plasma concentrations. Br. J. Psychiatry. 1985; 147: 283-288.

· Gerson, S.L., Arce, C. & Meltzer, H.Y. N-desmethylclozapine: a clozapine metabolite that suppresses haemopoiesis. Br. J. Haematol. 1994; 86: 555-561.

· Glassman, A.H. & Perel, J.M. Plasma levels and tricyclic antidepressants. Clin. Pharmacol. Ther. 1974 ; 16 (part. 2) : 198-200.

· Glassman, A.H., Kantor, S. & Shostak, M. Depression, delusions and drug response. Am. J. Psychiatry. 1975; 132 : 716-719.

· Glassman, A.H., Perel, J.M., Shostak, M. et al. Clinical implications of imipramine plasma levels for depressive illness. Arch. Gen. Psychiatry. 1977 ; 34 : 197-204.

· Glassman, A.H. & Bigger, J.T. Cardiovascular effects of therapeutic doses of tricyclic antidepressants. Arch. Gen. Psychiatry. 1981 ; 38 : 815-820.

· Glassman, A.H., Roose, S.P. & Bigger, J.T. Jr. The safety of tricyclic antidepressants in cardiac patients: risk-benefit reconsidered. JAMA. 1993; 269: 2673.

· Golden, R.N., DeVane, C.L., Laizure, S.C. et al. Bupropion in depression : the role of metabolites in clinical outcome. Arch. Gen. Psychiatry. 1985 ; 42 : 145-148.

· Golden, R.N., DeVane, C.L., Laizure, S.C. et al. Bupropion in depression, II: the role of metabolites in clinical outcome. Arch. Gen. Psychiatry. 1988; 45: 145-149.

· Goldman-Rakic, P. & Brown, R. Postnatal development of monamine content and synthesis in the cerebral cortex of rhesus monkeys. Dev. Brain. Res. 1982; 4: 339-349.

· Gomez, M.J., Garcia, M.J., Gonzalez, A.C. et al. Plasma protein binding kinetics of valproic acid over a broad dosage range : therapeutic implications. J. Clin. Pharm. Ther. 1993 ; 191-197.

· Goodnick, P.J. Blood levels and acute response to bupropion. Am. J. Psychiatry. 1992; 149: 399-400.

· Goodnick, P.J. & Sandoval, R. Blood levels and acute response to bupropion. Am. J. Psychiatry. 1992 ; 149 : 1690.

· Goodwin, F.K. & Jamison, K.R. Maniac-Depressive illness. N.Y., Oxford University Press, 1990.

· Gram, L.F. & Fredricson-Overo, K. Drug interaction : inhibitory effect of neuroleptics on metabolim of tricyclic antidepressants in man. Br. Med. J. 1972 ; 1 : 463-465.

· Gram, L.F. & Fredricson-Overo, K. First-pass metabolism of nortriptyline in man. Clin. Pharmacol. Ther. 1975 ; 18 : 305-314.

· Gram, L.F., Reisby, N., Ibsen, I., et al. Plasma levels and antidepressive effect of imipramine. Clin. Pharmacol. Ther. 1976 ; 19 : 318-324.

· Gram, L., Flachs, H., Wurtz-Jorgensen, A. et al. Sodium valproate, serum level and clinical effect in epilepsy : a controlled study. Epilepsia. 1979 ; 20 : 303-312.

· Greden, J.F. The laboratory in psychiatry. In Dunner, D.L. Current Psychiatric theraphy. W.B. Saunders Company. Philadelphia, 1993.

· Green, D.O. Clinical importance of doxepin antidepressant plasma levels. J. Clin. Psychiatry. 1979 ; 39 : 481-482.

· Greenblatt, D.J., DiMascio, A., Harmatz, J.S. et al. Pharmacokinetics and clinical effects of amantadine in drug-induced extrapyramidal symptoms. J. Clin. Pharmacol. 1977; 17: 704-708.

· Greenblatt, D.J., Sellers, E.M., Koch-Weser, J. Importance of protein binding for the interpretation of serum drug concentrations. J. Clin. Pharmacol. 1982 ; 22 : 259-263.

· Greenblatt, D.J., Harmatz, J.S. & Shader, R.I. Plasma alprazolam concentrations: relation to efficacy and side effects in the treatment of panic disorder. Arch. Gen. Psychiatry. 1993; 50:715-722.

· Greist, J.H., Chouinard, G., DuBoff, E. et al. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch. Gen. Psychiatry. 1995 ; 52 : 289-295.

· Grenngrass, P. & Tongue, S. The accumulation of noradrenaline and 5-hydroxytryptamine in three regions of mouse brain after tetrabenazine and iproniazid: effects of ethinyloestradiol and progesterone. Psychopharmacology. 1974; 39: 187-191.

· Gruvstad, M. Plasma levels of antidepressant and clinical response. Lancet. 1973 ; 1 : 95-96.

Principio de página

H-I

· Hale, T. Fluoxetine doses (letter). Lancet. 1991 ; 338 : 1521.

· Hammer, W. & Sjöqvist, F. Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. Life Sci. 1967 ; 6 : 1895-1903.

· Hanin, I., Koslow, S.H., Kocsis, J.H. et al. Cerebrospinal fluid levels of amitriptyline, nortriptyline, imipramine and desmethylimipramine. Relationship to plasma levels and treatment outcome. J. Affect. Disord. 1985; 9: 69-78.

· Haring, C., Meise, U., Humpel, C. et al. Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age. Psychopharmacology (Berl). 1989a; 99 (Suppl): S38-S40.

· Haring, C., Barnas, C., Saria, A. et al. Dose-related plasma levels of clozapine (letter). J. Clin. Psychopharmacol. 1989b; 9: 71- 72.

· Hasegawa, M., Gutierrez-Esteinou, R., Way, L. et al. Relationship between clinical efficacy and clozapine concnetrations in plasma in schizophrenia: effect of smoking. J. Clin. Psychopharmacol. 1993; 13: 383-390.

· Hasegawa, M., Cola, P.A. & Meltzer, H.Y. Plasma clozapine and desmethylclozapine levels in clozapine-induced agranulocytosis. Neuropsychopharmacology. 1994; 11: 45-47.

· Hillestad, L., Hansen, T., Melson, H. et al. Diazepam metabolism in normal man. I. serum concnetrations and clinical effects after intravenous, intramuscular, and oral administration. Clin. Pharmacol. Ther. 1974; 16: 479-484.

· Hillestad, L., Hansen, T. & Melson, H. Diazepam metabolism in normal man. II. Serum concnetration and clinical effect after oral administration and cumulation. Clin. Pharmacol. Ther. 1974; 16: 485-489.

· Hinderling, P.H. Red blood cells : a neglected compartment in pharmacokinetics and pharmacodynamics. Pharmacol. Rev. 1997 ; 49 : 279-298.

· Holmstrand, J., Anggard, E. & Gunne, L.M. Methadone maintenance: plasma level and therapeutic outcome. Clin. Pharmacol. Ther. 1978; 23: 175-180.

· Howart, B.G. & Grace, M. Depression, drugs, and delusions. Arch. Gen. Psychiatry. 1985 ; 42:1145-1147.

· Hrdina, P.D. & Lapierre, Y.D. Plasma levels of maprotiline and zimelidine and their relationship to clinical response in depressed patients. Ther. Drug Monit. 1986; 8: 400-406.

· Hughes, C. & Preskorn, S.H. Depressive syndromes in children and adolescents: diagnosis and treatment. Ann. Clin. Psychiatry. 1989; 1: 109-118.

· Hughes, C.W., Preskorn, S., Weller, E. et al. The effect of concomitant disorders in childhood depression on predicting treatment response. Psychopharmacol. Bull. 1990; 26: 235-238.

· Hurwitz, N. Predisposing factors in adverse reactions to drugs. Br. Med. J. 1969 ; 1 : 536-539.

· Insel, T.R., Murphy, D.L., Cohen, R.M. et al. Obsessive-compulsive disorder : a double-blind trial of clomipramine and clorgyline. Arch. Gen. Psychiatry. 1983 ; 40 : 605-612.

Principio de página

J

· Jacobsen, F.M. Low-dose valproate: a new treatment for cyclothymia, mild rapid-cycling disorders, and premenstrual syndrome. J. Clin. Psychiatry. 1993; 54: 229-234.

· Jain, U., Birmaher, B., Garcia, M. et al. Fluoxetine in children and adolescents with mood disorders: a chart review of efficacy and adverse effects. J. Child Adolesc. Psychopharmacol. 1992; 2: 259-265.

· Janicak, P.G., Javaid, J.I., Sharma, R.P. et al. Trifluoperazine plasma levels and clinical response. J. Clin. Psychopharmacol. 1989; 9: 340-346.

· Javaid, J.I., Janicak, P.G., Sharma, R.P. et al. Prediction of Haloperidol steady-state levels in plasma after a single test dose. J. Clin. Psychopharmacol. 1996; 16: 45-50.

· Jeste, D.V., Linnoila, M., Wagner, R. et al. Serum neuroleptic concentrations and tardive dyskinesia. Psychopharmacology. 1982; 76: 377-380.

· Jobson, K., Linnoila, M., Gillam, J. et al. Successful treatment of severe anxiety attacks with tricyclic antidepressants: a potential mechanism of action. Am. J. Psychiatry. 1978; 135: 863-864.

· Jungkunz, G. & Kuss, H.J. Amitriptyline and its demethylation rate (letter). Lancet. 1978 ; 2 : 1263-1264.

Principio de página

K

· Kane, J. & Smith, J. Tardive dyskinesia: prevalence and risk factors. Arch. Gen. Psychiatry. 1982; 39: 473-481.

· Kane, J., Honigfeld, G., Singer, J. et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry. 1988; 45: 789-796.

· Kangas, L., Kanto, J., Lehtinen, V. et al. Long-term nitrazepam treatment in psychiatric outpatients with insomnia. Psychopharmacology (Berl). 1979; 63: 63-66.

· Kappas, A., Anderson, K.E., Connery, A.H. et al. Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man. Clin. Pharmacol. Ther. 1976 ; 20 : 643-653.

· Kapur, S., Remington, G., Jones, C. et al. High levels of dopamine D2 receptor occupancy with low dose haloperdiol treatment: a PET study. Am. J. Psychiatry. 1996; 153: 948-950.

· Kapur, S., Zipursky, R., Roy, P. et al. The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Psychopharmacology. 1997: 131: 148-152.

· Karson, C.N., Newton, J.E.O., Livingston, R. et al. Human brain fluoxetine concentrations. J. Neuropsychiatry Clin. Neurosci. 1993; 5: 322-329.

· Kasper, S., Dötsch, Kick, H. et al. Plasma concentrations of fluvoxamine and maprotiline in major depression : implications on therapeutic efficacy and side effects. Eur. Neuropsyhopharmacol. 1993 ; 3 : 13-21.

· Keck, P.E., McElroy, S.L., Tugrul, K.C. et al. Valproate oral loading in the treatment of acute mania. J. Clin. Psychiatry. 1993 ; 54 : 305-308.

· Keller, M.B., Lavori, P.W., Kane, J.M. et al. Subsyndromal symptoms in bipolar disorder. A comparison of standard and low serum levels of lithium. Arch. Gen. Psychiatry. 1992 ; 49 : 371-376.

· Kelly, M.W., Perry, P.J., Holstead, S.G. & Garvey, J.M. Serum fluoxetine and norfluoxetine concentrations and antidepressant response. Ther. Drug Monit.. 1989 ; 11 : 165-170.

· Khalid, R., Amin, M.N. & Ban, T.A. Desipramine plasma levels and therapeutic response. Psychopharmacol. Bull. 1978 ; 14 : 43-44.

· Kilts, C.D. The ups and downs of oral lithium dosing. J. Clin. Psychiatry. 1998; 59 (suppl. 6): 21-26.

· Kirch, D.G., Bigelow, L.B., Korpi, E.R. et al. Serum haloperidol concentrations and clinical response in schizophrenia. Psychopharmacol. Bull. 1989; 14: 283-289.

· Kissling, W., Möller, H.J., Lauter, H. et al. Double-blind comparison of intravenous bversus oral maprotiline. Antidepressant activity, plasma concentrations, side-effects. Pharamcopsychiatry. 1985 ; 15 : 96-97.

· Kitanaka, I., Ross, R., Cutler, N. et al. Altered hydroxydesipramine concentrations in elderly depressed patients. Clin. Pharmacol. Ther. 1982 ; 31 : 51-55.

· Klok, C.J., Brouwer, G.J., van Praag, H.M. & Doogan, D.P. Fluvoxamine and chlomipramine in depressed patients. A double-blind clinical study. Acta Psychiatr. Scand. 1981 ; 64 : 1-11.

· Knott, C. & Reynolds, F. Therapeutic drug monitoring in pregnancy. Clin. Pharmacokinet. 1990; 19: 425 433.

· Ko, G.N., Korpi, E.R. & Kirch, D.G. Haloperidol and reduced haloperidol concentrations in plasma and red blood cells from chronic schizophrenic patients. J. Clin. Psychopharmacol. 1989; 9: 186-190.

· Koran, L.M., Cain, J.W., Dominguez, R.A. et al. Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder? Am. J. Psychiatry. 1996; 153: 1450-1454.

· Koreen, A.R., Lieberman, J., Alvir, J. et al. Relation of plasma fluphenazine levels to treatment response and extrapyramidal side effects in first-episode schizophrenic patients. Am. J. Psychiatry. 1994; 151: 35-39.

· Kragh-Sorensen, P., Asberg, M. & Eggert-Hansen, C. Plasma nortriptyline levels in endogenous depression. Lancet. 1973 ; 1 : 113-115.

· Kronig, M.H., Munne, R.A., Szymanski, S. et al. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am. J. Psychiatry. 1995; 152: 179-182.

· Kumar, V., Smith, R.C., Reed, K. & Leelavathi, D.E. Plasma levels and effects of nortriptyline in geriatric depressed patients. Acta Psychiatr. Scand. 1987 ; 75 : 20-28.

· Kupfer, D.J., Hanin, I., Spiker, D.G. et al. Amitriptyline plasma levels and clinical response in primary depression. Clin. Pharmacol. Ther. 1977 ; 22 : 904-911.

· Kutcher, S., Boulos, C., Ward, B. et al. Response to desipramine treatment in adolescent depression: a fixed dose, placebo-controlled trial. J. Am. Acad. Child Adolesc. Psychiatry. 1994; 33: 686-694.

· Kye, C.H., Waterman, G.S., Ryan, N.D. et al. A randomized, controlled trial of amitriptyline in the acute treatment of adolescent major depression. J. Am. Acad. Child Adolesc. Psychiatry. 1996; 35: 1139-1144.

· Kye, C. & Ryan, N.D. Pharmacologic treatment of child and adolescent depression. Child Adolesc. Psychiatr. Clin. North. Am. 1995; 4: 261-281.

Principio de página

L

· Lacro, J.P., Kuczenski, R., Roznoski, M. et al. Serum haloperidol levels in older psychotic patients. Am. J. Geriatric Psychiatry. 1996; 4: 229-236.

· Lam, Y.W.F., Jann, M.W. & Chang, W.H. Interconversion of haloperidol and reduced haloperidol. Clin. Pharmacol. Ther. 1991; 49: 135.

· Lane, H-Y., Lin, H-N., Hu, O.Y-P. et al. Blood levels of reduced haloperidol versus clinical efficacy and extrapyramidal side effects of haloperidol. Prog. Neuro-Psychopharmacol. & Biol. Psychiat. 1997; 21: 299-311.

· Laughren, T.P., Brown, W.A. & Williams, B.W. Serum prolactine and clinical state during neuroleptic treatment and withdrawal. Am. J. Psychiatry. 1979; 136: 108-110.

· Laursen, A.L., Mikkelsen, P.L., Rasmussen, A. & LeFevre, H.P. Paroxetine in the treatment of depression : a randomized comparison with amitriptyline. Acta Psychiatr. Scand. 1985 ; 71 : 249-255.

· Leonard, H.L., Meyer, M.C., Swedo, S.E. et al. Electrocardiographic changes during desipramine and clomipramine treatment in children and adolescents. J. Am. Acad. Child Adolesc. Psychiatry. 1995; 34: 1460-1468.

· Lesch, K.P., Hoh, A., Disselkamp-Tietze, J. et al. 5-Hydroxytryptamine1A receptor responsivity in obsessive-compulsive disorder: comparison of patients and controls. Arch. Gen. Psychiatry. 1991; 48: 540-547.

· Lesser, I.M. et al. Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia. Am. J. Psychiatry. 1992; 149:1556-1562.

· Levinson, D.F., Simpson, G.M., Singh, H. et al. Neuroleptic plasma level may predict response in patients who meet a criterion for improvement (letter). Arch. Gen. Psychiatry. 1988; 45: 877-879.

· Levinson, D.F., Simpson, G.M., Lo, E.S. et al. Fluphenazine plasma levels, dosage, efficacy, and side effects. Am. J. Psychiatry. 1995; 152: 765-771.

· Levy, G. Pharmacokinetic control and clinical interpretation of steady-state blood levels of drugs. Clin. Pharmacol. Ther. 1974 ; 16 (part 2) : 130-134.

· Liberman, R.P., Van Putten, T., Marshal, B.D. et al. Optimal drug and behavior therapy for treatment-refractory schizophrenic patients. Am. J. Psychiatry. 1994; 151: 756-759.

· Liisberg, P., Mose, H., Amdisen, A. et al. A clinical trial comparing sustained release amitriptyline (Saroten retard) and conventional amitriptyline tablets (Seroten) in endogenously depressed patients with simultaneous determination of serum levels of amitriptyline and nortrityline. Acta Psychiatr. Scand. 1978 ; 57 : 426-435.

· Lin, K.M. & Friedel, R.O. Relationship of plasma level of chlordiazepoxide and metabolites to clinical response. Am. J. Psychiatry. 1979; 136: 18-23.

· Lineberry, C.G., Johnston, J.A., Raymond, R.N. et al. A fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients. J. Clin. Psychiatry. 1990 ; 51 : 194-199.

· Lippmann, S., Manshadi, M., Regan, W. et al. The lithium index : too variable for use in clinical practice. Hosp. Com. Psychiatry. 1983 ; 34 : 71-72.

· Liu, H.C., Chang, W.H., Wei, F.C. et al. Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients. Ther. Drug Monit. 1996; 18: 200-207.

· Loo, H., Benyacoub, A.K., Rovei, V. et al. Long-term monitoring of tricyclic antidepressant plasma concentrations. Br. J. Psychiatr. 1980 ; 137 : 444-451.

· Lowry, M.R. & Dunner, F.J. Seizures during tricyclic therapy. Am. J. Psychiatry. 1980; 137: 1461-1462.

· Lydiard, R.B. Preliminary results of an open, fixed-dose study of desipramine in panic disorder. Psychopharmacol. Bull. 1987; 23: 139-140.

Principio de página

M

· Madakasira, S. & Khazanie, P.G. Reliability of amitryptiline dose prediction based on single-dose plasma levels. Clin. Pharmacol. Ther. 1985 ; 37 : 145-149.

· Magliozzi, J.R., Hollister, L.E., Arnold, K.V. et al. Relationship of serum haloperidol levels to clinical response in schizophrenia patients. Am. J. Psychiatry. 1981; 138: 365-367.

· Maj, M., Pirozzi, R., Magliano, L. et al. Long-term outcome of lithium prophylaxis in bipolar disorder : a 5-year prospective study of 402 patients at a lithium clinic. Am. J. Psychiatry. 1998 ; 155 : 30-35.

· Mann, J.J., Georgotas, A., Newton, R. & Gershon, S. Controlled study of trazodone, imipramine, and placebo in outpatients with endogenous depression. J. Clin. Psychopharmacol. 1981 ; 1 : 75-80.

· Marder, S.R., Van Putten, T., Aravagiri, M. et al. Fluphenazine plasma levels and clinical response. Psychopharmacol. Bull. 1990; 26: 256-259.

· Marder, S.R., Midha, K.K., Van Putten, T. et al. Plasma levels of fluphenazine in patients receiving fluphenazine decanoate: relationship to clinical response. Br. J. Psychiatry. 1991; 158: 658-665.

· Marder, S.R. The role of dosage and plasma levels in neuroleptic relapse prevention. Acta Psychiatr. Scand. 1994; 89 (suppl. 382): 25-27.

· Martensson, B., Nyberg, S., Toresson, G. et al. Fluoxetine treatment of depression. Acta Psychiatr. Scand. 1989 ; 79 : 586-596.

· Martin, G.I. & Zaug, P.J. ECG monitoring of enuretic children given imipramine. JAMA. 1973; 224: 902-903.

· Mattson, R.H. Antiepileptic drug monitoring : a reappraisal. Epilepsia. 1995 ; 36 (suppl. 5) : S22-S29.

· Matuzas, W., Javaid, J.I., Glass, R. et al. Plasma concentrations of imipramine and clinical response among depressed outpatients. J. Clin. Psychopharmacol. 1982 ; 2 : 140-142.

· Mavissakalian, M.R., Perel, J.M. & Michelson, L.K. The relationship of plasma imipramine and N-desmethylimipramine to improvement in agoraphobia. J. Clin. Psychopharmacol. 1984; 4: 36-40.

· Mavissakalian, M.R. & Perel, J.M. Imipramine dose-response relationship in panic disorder with agoraphobia. Arch. Gen. Psychiatry. 1989; 46: 127-131.

· Mavissakalian, M., Jones, B., Olson, S. et al. Clomipramine in obsessive-compulsive disorder: clinical response and plasma levels. J. Clin. Psychopharmacol. 1990a; 10: 261-268.

· Mavissakalian, M., Jones, B., Olson, S. et al. The relationship of plasma clomipramine and N-desmethylclomipramine to response in obsessive-compulsive disorder. Psychopharmacol. Bull. 1990b; 26 : 119-122.

· Mavissakalian, M.R., & Perel, J.M. Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships. Am. J. Psychiatry. 1995; 152: 673-682.

· Mavroidis, M.L., Kanter, D.R., Hirschowitz, J. et al. Clinical response and plasma haloperidol levels in schizophrenia. Psychopharmacology. 1983; 81: 354-356.

· Mavroidis, M.L., Kanter, D.R., Hirschowitz, J. et al. Clinical relevance of thiothixene plasma levels. J. Clin. Psychopharmacol. 1984a; 4: 155-157.

· Mavroidis, M.L., Kanter, D.R., Hirschowitz, J. et al. Fluphenazine plasma levels and clinical response. J. Clin. Psychiatry. 1984b; 45: 370-373.

· Mavroidis, M.L., Garver, D.L., Kanter, D.R. et al. Plasma haloperidol levels and clinical response: confounding variables. Psychopharmacol. Bull. 1985; 21: 62-65.

· May, P.R.A. & Van Putten, T. Plasma levels of chlorpromazine in schizophrenia. Arch. Gen. Psychiatry. 1978; 35: 1081-1087.

· May, P.R.A., Van Putten, T., Jenden, D.J. et al. Chlorpromazine levels and the outcome of treatment in schizophrenic patients. Arch. Gen. Psychiatry. 1981; 38: 202-207.

· McElroy, S.L., Keck, P.E. Jr., Pope, H.E. et al. Valproate in the treatment of rapid-cycling bipolar disorder. J. Clin. Psychopharmacol. 1988 ; 8 : 275-279.

· McElroy, S.L., Keck, P.E. Jr., Pope, H.E. et al. Valproate in the treatment of bipolar disorder : literature review and clinical guidelines. J. Clin. Psychopharmacol. 1992 ; 12 (suppl. 1) : 42S-52S.

· McEvoy, J.P., Stiller, R.L. & Farr, R. Plasma haloperidol levels drawn at neuroleptic threshold doses: a pilot study. J. Clin. Psychopharmacol. 1986: 6: 133-138.

· Meltzer, H.Y. & Fang, V.S. The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch. Gen. Psychiatry. 1976; 33: 279-286.

· Meltzer, H.Y., Goode, D.J., Schyve, P.M. et al. Effedct of clozapine on human serum prolactin levels. Am. J. Psychiatry. 1979; 136: 1551-1555.

· Mendlewicz, J., Linkowski, P. & Rees, J.A. A double-blind comparison of dothiepin and amitriptyline in patients with primary affective disorder : serum levels and clinical response. Br. J. Psychiatry. 1980 ; 136 : 154-160.

· Meszaros, K., Lenzinger, E., Hornik, K. et al. Biperiden and haloperidol plasma levels and extrapyramidal side effects in schizophrenic patients. Neuropsychobiology. 1997; 36: 69-72.

· Miller, D.D., Hershey, L.A., Duffy, J.P. et al. Serum haloperidol concentrations and clinical response in acute psychosis. J. Clin. Psychopharmacol. 1984; 4: 305-309.

· Miller, P., Beaumont, G., Seldrup, J. et al. Efficacy, side effects, plasma and blood concentrations of maprotiline (Ludiomil). J. Int. Med. Res. 1977 ; 5 (suppl. 4) : 101-111.

· Miller, R.S., Peterson, G.M., McLean, S. Monitoring plasma levels of fluphenazine during chronic therapy with fluphenazine decanoate. J. Clin. Pharm. Ther. 1995; 20: 55-62.

· Monteleone, P., Gnocchi, G. & Delrio, G. Plasma trazodone concentrations and clinical response in elderly depressed patients: a preliminary study. J. Clin. Psychopharmacol. 1989; 9: 284-287.

· Montgomery, S.A., Braithwaite, R.A. & Crammer, J.L. Routine nortriptyline levels in treatment of depression. Br. Med. J. 1977 ; 2 : 166-167.

· Montgomery, S.A., Braithwaite, R.A., Dawling, S. et al. High plasma nortriptyline levels in the treatment of depression, I. Clin. Pharmacol. Ther. 1978 ; 23 : 309-314.

· Montgomery, S.A., McAuley, R., Rani, S.J. et al. Amitriptyline plasma concentration and clinical response. Br. Med. J. 1979 ; 1 : 230-231.

· Moody, J., Tait, A. & Todrick, A. Plasma levels of imipramine and desmethylimipramine during therapy. Br. J. Psychiatry. 1967 ; 113 : 183-193.

· Mulgirigama, L.D., Pare, C.M.B., Turner, P. et al. Clinical response in depressed patients in relation to plasma concentrations of tricyclic antidepressants and tyramine pressor response. Postgrad. Med. J. 1977 ; 53 (suppl. 4) : 155-159.

· Musa, M.N. Nonlinear kinetics of trimipramine in depressed patients. J. Clin. Pharmacol. 1989; 29: 746-747.

· Muscettola, G., Goodwin, F.K., Potter, W.Z. et al. Imipramine and desipramine in plasma and spinal fluid. Arch. Gen. Psychiatry. 1978 ; 35 : 621-625.

Principio de página

N

· Neborsky, R.J., Janowsky, D.S., Perel, J.M. et al. Plasma/RBC haloperidol ratios and improvement in acute psychotic symptoms. J. Clin. Psychiatry. 1984; 45: 10-13.

· Nelson, J.C., Bock, J.L. & Jatlow. P.I. Clinical implications of 2-hydroxydesipramine plasma concentrations. Clin. Pharmacol. Ther. 1983 ; 33 : 183-189.

· Neslon, J.C. Use of desipramine in depressed inpatients. J. Clin. Psychiatry. 1984 ; 45 (10, sec 2) : 10-15.

· Nelson, J.C., Jatlow, P.I. & Mazure, C. Desipramine plasma levels and response in elderly melancholic patients. J. Clin. Psychopharmacol. 1985 ; 5 : 217-220.

· Nelson, J.C., Price, L.H. & Jatlow, P.I. Neuroleptic dose and desipramine concentrations during combined treatment of unipolar delusional depression. Am. J. Psychiatry. 1986 ; 143 : 1151-1154.

· Nelson, J.C., Jatlow, P.I. & Mazure, C. Rapid desipramine dose adjustment using 24-hour levels. J. Clin. Psychopharmacol. 1987 ; 7 : 72-77.

· Nies, A., Robinson, D.S., Friedman, M.J. et al. Relationship between age and tricyclic antidepressant plasma levels. Am. J. Psychiatry. 1977 ; 134 : 790-793.

· Noguchi, T., Shimoda, K. & Takahashi, S. Clinical significance of plasma levels of clomipramine, its hydroxylated and desmethylated metabolites: prediction of clinical outcome in mood disorders using discriminant analysis of therapeutic drug monitoring data. J. Affect. Disord. 1993; 29: 267-279.

· Nordin, C., Bertilsson, L. & Siwers, B. CSF and plasma levels of nortriptyline and its 10-hydroxy metabolite. Br. J. Clin. Pharmacol. 1985; 20: 411-413.

· Nordström, A-L., Farde, L., Wiesel, F-A. et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double blind PET study of schizophrenic patients. Biol. Psychiatry. 1993; 33: 227-235.

· Nordström, A-L., Farde, L., Nyberg, S. et al. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentrations: a PET study of schizophrenic patients. Am. J. Psychiatry. 1995; 152: 1444-1449.

· Nordström, A-L. & Farde, L. Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients. J. Clin. Psychopharmacol. 1998; 18: 305-310.

· Norman, T.R., Burrows, G.D., Maguire, K.P. et al. Maprotiline in affective illness. J. Affect. Disord. 1983 ; 5 : 147-154.

· Noyes, R. Jr., Garvey, M.J., Cook, B.L. et al. Problems with tricyclic antidepressant use in patients with panic disorder or agoraphobia: results of a naturalistic follow-up study. J. Clin. Psychiatry. 1989; 50: 163-169.

· Nurnberg, H.G. & Coccaro, E.F. Response of panic disorder and resistance of depression to imipramine. Am. J. Psychiatry. 1982; 139: 1060-1062.

· Nyberg, S., Farde, L., Halldin, C. et al. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am. J. Psychiatry. 1995 ; 152 : 173-178.

Principio de página

O-P

· Orsulak, P.J., Sink, M. & Weed, J. Blood collection tubes for tricyclic antidepressant drugs: a reevaluation. Ther. Drug. Monit. 1984; 6: 444-448.

· Palao, D.J., Arauxo, A., Brunet, M. et al. Haloperidol: therapeutic window in schizophrenia. J. Clin. Psychopharmacol. 1994; 14: 303-310.

· Papadopoulos, A.S., Chand, T.G., Crammer, J.L. et al. A pilot study of plasma thioridazine and metabolites in chronically treated patients. Br. J. Psychiatry. 1980; 136: 591-596.

· Parry, B.L. Reproductive factors affecting the course of affective illness in women. Psychiatr. Clin. North Am. 1989 ; 12 : 207-220.

· Pascalis, G., Wargny, E., Lamiable, D. et al. Clomipramine and demethylclomipramine. Correlation of plasma levels and efficacy in 24 depressive patients. Encephale. 1987; 13: 239-244.

· Pato, M.T., Murphy, D.L. & De Vane, C.L.. Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation (letter). J. Clin. Psychopharmacol. 1991 ; 11 : 224-225.

· Perry, P.J., Pfohl, B.M. & Kelly, M.W. The relationship of haloperidol concnetrations to therapeutic response. J. Clin. Psychopharmacol. 1988; 8: 38-43.

· Perry, P.J., Miller, D., Arndt, S.V. et al. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am. J. Psychiatry. 1991; 148: 231-235.

· Perry, P.J., Sanger, T. & Beasley, C. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients. J. Clin. Psychopharmacol. 1997; 17: 472-477.

· Petit, J.M., Spiker, D.G., Ruwitch, J.F. et al. Tricyclic antidepressant plasma levels and adverse effects after overdose. Clin. Pharmacol. Ther. 1977 ; 21 : 47-51.

· Petti, T. & Law, W. Imipramine treatment of depressed children: a double-blind pilot study. J. Clin. Psychopharmacol. 1982; 2: 107-110.

· Peyre, F., Verdoux, H. & Bourgeois, M. Fluvoxamine. Etude de la relation posologies-taux plasmatiques sur un groupe de 80 déprimés. Lencéphale. 1992 ; 17 : 76-78.

· Physicians' Desk Reference. 50th ed. Montvale, NJ : Medical Economics, 1996.

· Piafsky, K.M. & Borga, O. Plasma protein binding of basic drugs. II. Importance of alpha-1-acid glycoprotein for interindividual variation. Clin. Pharmacol. Ther. 1977 ; 22 : 545-549.

· Pickar, D., Owen, R.R., Litman, R.E. et al. Clinical and biologic response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Arch. Gen. Psychiatry. 1992; 49: 345-353.

· Pollack, S., Lieberman, J., Kleiner, D. et al. High plasma clozapine levels in tardive dyskinesia. Psychopharmacol. Bull. 1993; 29: 257-262.

· Pope, H.G. Jr., McElroy, S.L., Keck, P.E. Jr. et al. Valproate in the treatment of acute mania: a placebo-controlled study. Arch. Gen. Psychiatry. 1991; 48: 62-68.

· Post, R.M., Uhde, T.W., Ballenger, J.C. et al. Carbamazepine and its 10,11-epoxide metabolite in plasma and CSF. Relationship to antidepressant response. Arch. Gen. Psychiatry. 1983 ; 40 : 673-676.

· Potkin, S.G., Shen, Y., Zhou, D. et al. Does a therapeutic window for plasma haloperidol exist? Preliminary chinese data. Psychopharmacol. Bull. 1985; 21: 59-61.

· Potkin, S.G., Bera, R., Gulasekaram, B. et al. Plasma clozapine concentrations predict clinical response in treatmewnt-resistant schizophrenia. J. Clin. Psychiatry. 1994; 55 (suppl. B): 133-136.

· Potter, W., Zavadil, A., Kopin, I. & Goodwin, F. Single dose kinetics predict steady-state concnetrations of imipramine and desipramine. Arch. Gen. Psychiatry. 1980 ; 37 : 314-320.

· Preskorn, S.H. & Simpson, S. Tricyclic antidepressant induced delirium and plasma drug concentration. Am. J. Psychiatry. 1982 ; 139 : 822-823.

· Preskorn, S.H., Weller, E.B. & Weller, R.A. Depression in children : relationship between plasma imipramine levels and response. J. Clin. Psychiatry. 1982 ; 43 : 450-453.

· Preskorn, S.H. Antidepressant response and plasma concentrations of bupropion. J. Clin. Psychiatry. 1983 ; 44 : 137-139.

· Preskorn, S.H., Weller, E.B., Weller, R.A. et al. Plasma leveles of imipramine and adverse effects in children. Am. J. Psychiatry. 1983 ; 140 : 1332-1335.

· Preskorn, S.H., Weller, E.B., Hughes, C.W. et al. Depression in prepuberal children : dexamethasone nonsupression predicts differential response to imipramine vs. placebo. Psychopharmacol. Bull. 1987 ; 23 : 128-133.

· Preskorn, S.H. & Katz, S.E. Bupropion plasma levels : intraindividual and interindividual variability. Ann. Clin. Psychiatry. 1989 ; 1 : 59-61.

· Preskorn, S.H. & Jerkovich, G. Central nervous system toxicity of tricyclic antidepressants : phenomenology, course, risk factors, and role of therapeutic drug monitoring. J. Clin. Psychopharmacol. 1990 ; 10 : 88-95.

· Preskorn, S.H., Fleck, R.J. & Schreoder, D.H. Therapeutic drug monitoring of bupropion. Am. J. Psychiatry. 1990 ; 147 : 1690.

· Preskorn, S.H., Silkey, B., Beber, J. & Dorey, C. Antidepressant response and plasma concnetration of fluoxetine. Ann. Clin. Psychiatry. 1991 ; 3 : 147-153.

· Preskorn, S.H. & Fast, G. Therapeutic drug monitoring for antidepressants : efficacy, safety, and cost effectiveness. J. Clin. Psychiatry. 1991 ; 52 (suppl. 6) : 23-33.

· Preskorn, S.H. Dose-effect and concentration-effect relationships with new antidepressants. In Gram, L.F., Balant, L.P., Meltzer, H.Y. & Dahl, S.G. (eds.). Clinical Pharmacology in Psychiatry. Springer-Verlag. Berlin, 1993a. pp : 174-189.

· Preskorn, S.H. Pharmacokinetics of antidepressants: why and how they are relevant to treatment. J. Clin. Psychiatry. 1993b; 54 (suppl.): 14-34.

· Puig-Antich, J., Perel, J. & Lupatkin, W. Plasma levels of imipramine and desipramine in clinical response in prepuberal major depressive disorder. J. Am. Acad. Child Psychiatry. 1979 ; 18 : 616-627.

· Puig-Antich, J., Perel, J.M., Lupatkin, W. et al. Imipramine in prepuberal major depressive disorders. Arch. Gen. Psychiatry. 1987; 44 : 81-89.

Principio de página

Q-R

· Quitkin, F.M., Rifkin, A. & Klein, D.F. Imipramine response in deluded depressive patients. Am. J. Psychiatry. 1978 ; 135: 806-811.

· Rane, A., Hojer, B. & Wilson, J.T. Kinetics of carbamazepine and its 10,11 epoxide metabolite in children. Clin. Pharmacol. Ther. 1976 ; 19 : 276-283.

· Rapoport, J.L., Mikkelsen, E.J., Zavadil, A. et al. Childhood enuresis II: Psychopathology, tricyclic concentration in plasma, and antienuretic effect. Arch. Gen. Psychiatry. 1980; 37: 1146-1152.

· Reifler, B.V., Ward, N., Davis, C.M. et al. Thiothixene plasma levels and clinical response in acute schizophrenia. J. Clin. Psychhiatry. 1981; 42: 207-211.

· Reimherr, F.W., Byerley, W.F., Ward, M.F. et al. Sertraline, a selective inhibitor of serotonin uptake, for the treatment of outpatients with major depressive disorder. Psychopharmacol. Bull. 1988 ; 24 : 200-205.

· Relling, M.V., Lin, J.S., Ayers, G.D. et al. Racial and gender differences in N-acetyl-transferase, xanthine oxidase and CYP1A2 activities. Clin. Pharmacol. Ther. 1992 ; 52 : 643-658.

· Remington, G., Kapur, S. & Zipursky, R. The relationship between risperidone plasma levels and dopamine D2 occupancy: a positron emission tomographic study (letter). J. Clin. Psychopharmacol. 1998, 18: 82-83.

· Renshaw, P.F., Guimaraes, A.R., Fava, M. et al. Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration. Am. J. Psychiatry. 1992; 149: 1592-1594.

· Riddle, M.A., Nelson, J.C., Kleinman, C.S. et al. Sudden death in children receiving Norpramin: a review of three reported cases and commentary. J. Am. Acad. Child Adolesc. Psychiatry. 1991; 30 :104-108.

· Riddle, M., Geller, B. & Ryan, N. Another sudden death in a child treated with desipramine. J. Am. Acad. Child Adolesc. Psychiatry. 1993; 32: 792-797.

· Rigal, J.G., Albin, H.C., Duchier, A.R. et al. Imipramine blood levels and clinical outcome. J. Clin. Psychopharmacol. 1987; 7: 222-229.

· Rimón, R., Kampman, R., Laru-Sompa, R. et al. Serum and cerebrsopinal fluid levels of fluphenazine - relationship to treatment response in schizophrenic patients. Hum. Psychopharmacol. 1986; 1: 23-27.

· Risch, S.C., Huey, L.Y. & Janowsky, D.S. Plasma levels of tricyclic antidepressants and clinical efficiency : review of the literature. J. Clin. Psychiatry. 1979 ; 40 : 4-16.

· Risch, S.C., Kalin, N.H., Janowsky, D.S. & Huey, L.Y. Indications and guidelines for plasma tricyclic antidepressant concentration monitoring. J. Clin. Psychopharmacol. 1981 ; 1 : 59-63.

· Rivera-Calimlim, R., Casteneda, L. & Lasagna, L. Effects of mode of management on plasma chlorpromazine in psychiatric patients. Clin. Pharmacol. Ther. 1973; 14: 978-986.

· Rivera-Calimlim, R., Nasrallah, H., Strauss, J. et al. Clinical response and plasma levels: effect of dose, dosage schedules, and drug interactions on plasma chlorpromazine levels. Am. J. Psychiatry. 1976; 133: 646-652.

· Robinson, D.S., Cooper, T.B., Haward, D. et al. Amitriptyline and hydroxylated metabolite plasma levels in depressed outpatients. J. Clin. Psychopharmacol. 1985; 5: 83-88.

· Rosse, R.B.; Deutsch, L.H. & Deutsch, S,I. Medical assessment and laboratory testing in psychiatry. In Kaplan, H.I. & Sadock, B. Comprehensive Textbook of Psychiatry. 6th edn. W & W. Baltimore, 1995.

· Rubin, E.H., Biggs, J.T. & Preskorn, S.H. Nortriptyline pharmacokinetics and plasma levels : implications for clinical practice. J. Clin. Psychiatry. 1985 ; 46 : 418-424.

· Rudorfer, M.V. & Young, R.C. Desipramine: cardiovascular effects and plasma levels. Am. J. Psychiatry. 1980; 137: 984-986.

· Ryan, N., Puig-Antich, J., Cooper, T. et al. Imipramine in adolescent major depression: plasma level and clinical response. Acta Psychiatr. Scand. 1986; 73: 275-288.

· Ryan, N., Puig-Antich, J., Ambrosini, P. et al. The clinical picture of major depression in children and adolescents. Arch. Gen. Psychiatry. 1987; 44: 854-861.

Principio de página

S

· Sakalis, G., Curry, S.H., Mould, G.P. et al. Physiologic and clinical effects of chlorpromazine and their relation to plasma level. Clin. Pharmacol. Ther. 1972; 13: 931-946.

· Santos, J.L., Cabranes, J.A., Almoguera, I. et al. Clinical implications of determination of plasma haloperidol levels. Acta Psychiatr. Scand. 1989; 79: 348-354.

· Sathananathan, G.L., Gershon, S., Almeida, M. et al. Correlation between plasma and cerebrospinal levels of imipramine. Arch. Gen. Psychiatry. 1976 ; 33 : 1109-1110.

· Schmider, J., Greenblatt, D.J., Von Moltke, L. & Shader, R.I. Relationship of in vitro data on drug metabolism to in vivo pharmacokinetics and drug interactions : implications for diazepam disposition in humans (editorial). J. Clin. Psychopharmacol. 1996 ; 16 : 267-.272.

· Schulz, S.C., Butterfield, L., Garicano, M. et al. Beyond the therapeutic window: a case presentation. J. Clin. Psychiatry. 1984; 45: 223-225.

· Schweizer, E., Rickels, K., Amsterdam, J.D. et al. What constitutes an adequate antidepressant trial for fluoxetine. J. Clin. Psychiatry. 1990 ; 51 : 8-11.

· Schweizer, E., Rickels, K., Weiss, S. et al. Maintenance drug treatment of panic disorder. Arch. Gen. Psychiatry. 1993; 50: 51-60.

· Scoggins, B.A., Maguire, K.P., Norman, T.R. & Burrows, G.D. Measurement of tricyclic antidepressants. Part I. A review of methodology. Clin. Chem. 1980 ; 26 : 5-17.

· Shimoda, K., Yasuda, S., Morita, S. et al. Significance of monitoring plasma levels of amitriptyline, and its hydroxylated and desmethylated metabolites in prediction of the clinical outcome of depressive state. Psychiatr. Clin. Neurosc. 1997; 51: 35-41.

· Shostak, M., Perel, J.M., Stiller, R.L. et al. Plasma haloperidol and clinical response: a role for reduced haloperdiol in antipsychotic activities? J. Clin. Psychopharmacol. 1987; 7: 394-400.

· Simpson, G.M. & Cooper, T.A. Clozapine plasma levels and convulsions. Am. J. Psychiatry. 1978; 135: 99-100.

· Simpson, G.M., Cooper, T.B., Bark, N. et al. Effect of antiparkinsonian medication on plasma levels of chlorpromazine. Arch. Gen. Psychiatry. 1980; 37: 205-208.

· Simpson, G.M. & Kashinat, Y. Blood levels of neuroleptics: state of the art. J. Clin. Psychiatry. 1985; 46: 22-28.

· Simpson, G.M., Pi, E.H., Gross, L. et al. Plasma levels and therapeutic response with trimipramine treatment of endogenous depression. J. Clin. Psychiatry. 1988; 49: 113-116.

· Smith, R.C., Crayton, J., Dekirmenjian, H. et al. Blood levels of neuroleptic drugs in nonresponding chronic schizophrenic patients. Arch. Gen. Psychiatry. 1979; 36: 579-584.

· Smith, R.C., Vroulis, G., Shvartsburd, A. et al. RBC and plasma haloperidol and clinical response in schizophrenia. Am. J. Psychiatry. 1982; 139: 1054-1056.

· Smith, R.C., Baumgartner, R., Misra, C.H. Haloperidol, plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical versus radioreceptor plasma level assay. Arch. Gen. Psychiatry. 1984; 41: 1044-1049.

· Smith, R.C., Baumgartner, R., Burd, A. et al. Haloperidol and thioridazine drug levels and clinical response in schizophrenia: comparison of gas-liquid chromatographic and radioreceptor drug level assays. Psychopharmacol. Bull. 1985; 21: 52-58.

· Smith, R.C. Plasma haloperidol levels and clinical response. Arch. Gen. Psychiatry. 1987; 44: 1110-1112.

· Sögüt, Ö, Yalcinkaya, C., Saygili, R. et al. An attempt to predict daily erythrocyte lithium fluctuations. Eur. J. Drug Metab. Pharmacokinet. 1995 ; 20 : 271-274.

· Spar, J.E. Plasma trazodone concentrations in elderly depressed inpatients : cardiac effects and short-term efficacy. J. Clin. Psychopharmacol. 1987 ; 7 : 406-409.

· Sperner-Unterweger, B., Gaggl, S., Fleischhacker, W.W. et al. Effects of clozapine on hematopoiesis and the cytokine system. Biol. Psychiatry. 1993; 34: 536-543.

· Spina, E., Gitto, C., Avenoso, A. et al. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. Eur. J. Clin. Pharmacol. 1997; 51: 395-398.

· Stern, R.S., Marks, I.M., Mawson, D. & Luscombe, D.K. Clomipramine and exposure for compulsive rituals : II. Plasma levels, side effects and outcome. Br. J. Psychiatry. 1980 ; 136 : 161-166.

· Stern, S.L. & Walters, M. Plasma tricyclics levels : mistaken identity. Lancet. 1983 ; 1 : 993.

· Stern, S.L., Cooper, T.B., Nelson, L.D. et al. 2-Hydroxydesipramine and desipramine plasma levels: how are they related to antidepressant response? Int. Clin. Psychopharmacol. 1996; 11: 219-227.

· Stewart, R.B. & Cluff, L.E. A review of medication errors and compliance in ambulant patients. Clin. Pharmacol. Ther. 1972 ; 13 : 463-468.

· Strober, M., Freeman, R. & Rigali, J. The pharmacotherapy of depressive illness in adolescence: I. An open label trial of imipramine. Psychopharmacol. Bull. 1990; 26: 80-84.

· Swigar, M.E., Jatlow, P.I., Goicoechea, N. et al. Ratio of serum prolactin to haloperidol and early clinical outcome in acute psychosis. Am. J. Psychiatry. 1984; 14: 1281-1283.

Principio de página

T

· Tansella, M., Siciliani, O., Burti, L. et al. N-Desmethyldiazepam and amylobarbitone sodium as hypnotics in anxious patients: plasma levels, clinical efficacy and residual effects. Psychopharmacologia. 1975; 41: 81-85.

· Tasker, T.C.G., Kaye, C.M., Zussman, B.D. & Link, C.G.G. Paroxetine plasma concentrations : lack of correlation with efficacy or adverse events. Acta Psychiatr. Scand. 1989 ; 80 (suppl. 350) : 152-155.

· Thompson, T.L., Moran, M.G. & Neis, A.S. Psychotropic drug use in the elderly. N. Engl. J. Med. 1983 ; 308 : 134-138, 194-199.

· Thoren, P., Asberg, M., Bertilsson, L. et al. Clomipramine treatment of obsessive-compulsive disorder. Arch. Gen. Psychiatry. 1980 ; 37 : 1289-1294.

· Thorup, M. & Fog, R. Clozapine treatment of schizophrenic patients: plasma concentrations and coagulation factors. Acta Psychiatr. Scand. 1977; 55: 123-126.

· Tollefson, G.D., Beasley, C.M., Tran, P.V. et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am. J. Psychiatry. 1997; 154: 457-465.

· Tomson, T., Tybring, G., Bertilsson, L. et al. Carbamazepine therapy in trigeminal neuralgia : clinical effects in relation to plasma concentration. Arch. Neurol. 1980 ; 37 : 699-703.

· Tune, L.E., Creese, I., De Paulo, J.R. et al. Clinical state and serum neuroleptic levels measured by radioreceptor assay in schizophrenia. Am. J. Psychiatry. 1980; 137: 187-190.

· Tune, L.E., Steele, C. & Cooper, T. Neuroleptic drugs in the management of behavioral symptoms of Alzheimer's disease. Psychiatr. Clin. North. Am. 1991; 14: 353-373.

· Tyrer, S.P., Marshall, E.F. & Griffiths, H.W. The relationship between response to fluoxetine, plasma drug levels, imipramine binding to platelet membranes and whole-blood 5-HT. Prog. Neuropsychopharmacol. Biol. Psychiatry. 1990; 14: 797-805.

Principio de página

V

· Van Putten, T., Marder, S.R., May. P.R.A. et al. Plasma levels of haloperidol and clinical response. Psychopharmacol. Bull. 1985; 21: 69-72.

· Van Putten, T. & Marder, S.R. Variable dose studies probit misleading therapeutic windows. J. Clin. Psychopharmacol. 1986; 6: 55-56.

· Van Putten, T., Marder, S.R., Mintz, J. et al. Haloperidol plasma levels and clinical response: a therapeutic window relationship. Psychopharmacol. Bull. 1988; 24: 172-175.

· Van Putten, T, Marder, S.R. & Mintz, J. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch. Gen. Psychiatry. 1990; 47: 754-758.

· Van Putten, T., Marder, S.R., Wirshing, W.C. et al. Neuroleptic plasma levels. Schizophr. Bull. 1991a; 17: 197-216.

· Van Putten, T., Marder, S.R. & Mintz, J. Serum prolactin as correlate of clinical response to haloperidol. J. Clin. Psychopharmacol. 1991b; 11: 357-361.

· Van Putten, T., Aravagiri, M., Marder, S.R. et al. Plasma fluphenazine levels and clinical response in newly admitted schizophrenic patients. Psychopharmacol. Bull. 1991c; 27: 91-96.

· Van Putten, T., Marder, S.R., Mintz, J. et al. Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am. J. Psychiatry. 1992; 149: 500-505.

· VanderZwaag, C., McGee, M., McEvoy, J.P. et al. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am. J. Psychiatry. 1996; 153: 1579- 1584.

· Verghese, A., Indrani, I., Kuruvilla, K. et al. Usefulness of saliva lithium estimation. Br. J. Psychiatry. 1977 ; 130 : 148-150.

· Vesell, E.S. Factors causing interindividual variations of drug concentrations in blood. Clin. Pharmacol. Ther. 1974 ; 16 (part. 2) : 135.

· Veste, D.V., Rosenblatt, J.E., Wagner, R.L. et al. High serum neuroleptic levels in tardive dyskinesia? N. Engl. J. Med. 1979; 301: 1184.

· Volavka, J., Cooper, T.B., Meisner, M. et al. Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder: a progress report. Psychopharmacol. Bull. 1990; 26: 13-17.

· Volavka, J., Cooper, T.B., Czobor, P. et al. Haloperidol blood levels and clinical effects. Arch. Gen. Psychiatry. 1992; 49: 354-361.

· Volavka, J., Thomas, B., Cooper,. M.A. et al. Plasma haloperdol levels and clinical effects in schizophrenia and schizoaffective disorders. Arch. Gen. Psychiatry. 1995; 52: 837-845.

Principio de página

W-Y

· Ward, N.G., Bloom, V.L., Wilson, L. et al. Doxepin plasma levels and therapeutic response in depression : preliminary findings. J. Clin. Psychopharmacol. 1982 ; 2 : 126-128.

· Ward, M.E., Musa, M.N. & Bailey, L. Clinical pharmacokinetics of lithium. In Musa, M.N. Pharmacokinetics and therapeutic drug monitoring of psychiatric drugs. Thomas books. Springfield, 1993.

· Watson, I.D. & Stewart, M.J. Separation and quantitative determination of tricyclic antidepressants by high-performance liquid chromatography. J. Chromatogr. 1975 ; 110 : 389-392.

· Weissman, M., Gammon, G., John, K. et al. Children of depressed parents: increased psychopathology and early onset of major depression. Arch. Gen. Psychiatry. 1987; 44: 847-853.

· Weller, E.B., Weller, R.A. & Preskorn, S.H. et al. Steady-state plasma imipramine levels in prepuberal depressed children. Am. J. Psychiatry. 1982 ; 139 : 506-508.

· Wernicke, J.F., Dunlop, S.R., Dornseif, B.E. & Zerbe, R.L. Fixed dose fluoxetine therapy for depression. Psychopharmacol. Bull. 1987 ; 23 : 164-168.

· Wernicke, J.F., Dunlop, S.R., Dornseif, B.E. et al. Low-dose fluoxetine therapy for depression. Psychopharmacol. Bull. 1988 ; 24 : 183-188.

· Werstiuk, E.S., Grof, P., Rotstein, E. et al. Effect of combined haloperidol-lithium treatment on vitro RBC lithium uptake in patients with affective disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry. 1983; 7: 831-834.

· Wilens, T.E., Biederman, J., Baldessarini, R.J. et al. Electrocardiographic effects of desipramine and 2-hydroxydesipramine in children, adolescents, and adults treated with desipramine. J. Am. Acad. Child Adolesc. Psychiatry. 1993a; 32: 798-804.

· Wilens, T.E., Biederman, J., Spencer, T. et al. A retrospective study of serum levels and electrocardiographic effects of nortriptyline in children and adolescents. J. Am. Acad. Child Adolesc. Psychiatry. 1993b; 32: 270-277.

· Wincor, M.Z., Munjack, D.J. & Palmer, R. Alprazolam levels and response in panic disorder: preliminary results. J. Clin. Psychopharmacol. 1991; 11: 48-51.

· Wisner, K.L., Perel, J.M. & Wheeler, S.B. Tricyclic Dose Requirements Across Pregnancy. Am. J. Psychiatry. 1993; 150: 1541-1542.

· Wistedt, B., Jorgensen, A. & Wiles, D. A depot neuroleptic withdrawal study. Plasma concenetration of fluphenazine and flupenthixol and relapse frequency. Psychopharmacology. 1982; 78: 301-304.

· Wode-Helgodt, B., Borg, S., Fyro, B. et al. Clinical effects and drug concentrations in plasma and cerebrospinal fluid in psychotic patients treated with fixed doses of chlorpromazine. Acta Psychiatr. Scand. 1978; 58: 149-173.

· Wolkin, A., Brodie, J., Barouche, F. et al. Dopamine receptor occupancy and plasma haloperidol levels (letter). Arch. Gen. Psychiatry. 1989; 46: 482-483.

· Yesavage, J.A., Becker, J., Werner, P.D. et al. Serum level monitoring of thiothixene in schizophrenia: acute single-dose levels at fixed doses. Am. J. Psychiatry. 1982; 139: 174-178.

· Yonkers, K.A., Kando, J.C., Cole, J.O. & Blumenthal, S. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am. J. Psychiatry. 1992 ; 149 : 587-595.

· Young, R.C., Alexopoulos, G.S., Shamolan, C.A. et al. Plasma 10-hydroxynortriptyline in elderly depressed patients. Clin. Pharmacol. Ther. 1984 ; 35 : 540-544.

Principio de página

Z

· Zetin, M., Garber, D., De Antonio, M. et al. Prediction of lithium dose : a mathematical alternative to the test-dose method. J. Clin. Psychiatry. 1986 ; 47 : 175-178.

· Ziegler, V.E., Clayton, P.J., Taylor, J.R. et al. Nortriptyline plasma levels and therapeutic response. Clin. Pharmacol. Ther. 1976a ; 20 : 458-463.

· Ziegler, V.E., Co, B.T., Taylor, J.R. et al. Amitriptyline plasma levels and therapeutic response. Clin. Pharmacol. Ther. 1976b ; 19 : 795-801.

· Ziegler, V.E. & Biggs, J.T. Tricyclic plasma levels: effect of age, race, sex and smoking. JAMA. 1977 ; 238 : 2167-2169.

· Ziegler, V.E., Knesevich, J.W., Wylie, L.T. & Biggs, J.T. Sampling time, dosage schedule, and nortriptyline plasma levels. Arch. Gen. Psychiatry. 1977a ; 34 : 613-615.

· Ziegler, V.E., Meyer, D.A., Rosen, S.H. et al. Amitriptyline dosage schedule, sampling time and tricyclic plasma levels. Br. J. Psychiatry. 1977b ; 131 : 168-171.

· Ziegler, V.E., Clayton, P.J. & Biggs, J.T. A comparison study of amitriptyline and nortriptyline with plasma levels. Arch. Gen. Psychiatry. 1977c ; 34 : 607-612.

· Ziegler, V.E., Co, B.T. & Biggs, J.T. Plasma nortriptyline levels and ECG findings. Am. J. Psychiatry. 1977d ; 134 : 441-443.

· Ziegler, V.E., Biggs, J.T., Rosen, S.H. et al. Imipramine and desipramine plasma levels : relationship to dosage schedule and sampling time. J. Clin. Psychiatry. 1978a ; 36 : 660-663.

· Ziegler, V.E., Biggs, J.T., Wylie, L.T. et al. Doxepin kinetics. Clin. Pharmacol. Ther. 1978b ; 23 : 573-579.

Ziegler, V.E., Taylor, J.R., Wetzel, R.D. et al. Nortriptyline plasma levels and subjective side effects. Br. J. Psychiatry. 1978c ; 132 : 55-60.

Principio de página

Comentarios Principio de página